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ABSTRACT
 
Aims
 
This study evaluates the suitability of  gas chromatographic-mass spec-
trometric (GC-MS) analysis to follow-up the extent of  benzodiazepine (mis)use
in a Belgian prison population and compares it to other analytical strategies
(e.g. screening followed by confirmation of  the positive samples).
 
Design and participants
 
From February to August 1998, 598 persons were
jailed of  which 188 (31.4% of  the incoming detainees) volunteered to be
screened. Urine samples (530 in total) were collected on the day of  arrival and
after 14, 30 and 90 days of  imprisonment.
 
Measurements
 
All samples were screened by EMIT
 
®
 
 for benzodiazepines and
analysed subsequently by GC-MS.
 
Findings
 
EMIT
 
®
 
 screening yielded 117 (22.1%) positive samples, a number
which increased to 174 (32.8%) after GC-MS analysis. Of  these 174 GC-MS pos-
itive samples, 119 (68.4%) contained one benzodiazepine while for the remain-
ing samples multiple benzodiazepine (mis)use could be demonstrated. A
significant increase in benzodiazepine (mis)use was indicated only from day 0 to
day 14 based on the GC-MS results but not on the immunoassay results, even
when the latter were complemented with GC-MS analysis of  the positively
screened samples. The GC-MS data also demonstrated that benzodiazepines are
mainly (mis)used by subjects on benzodiazepine prescription as almost 50% of
these subjects took additional non-prescribed benzodiazepines. During GC-MS
analysis other drugs were co-extracted unintentionally and chromatographed
and 23.9% of  the volunteers were positive for illegal drugs on the day of  arrival.
 
Conclusion
 
Immunoassay results yield an underestimation of  the problem of
benzodiazepine (mis)use in prison due to the high false negative rate. GC-MS
analysis of  all samples therefore is the recommended strategy for this type of  lon-
gitudinal study as it yields more correct and detailed information than the
immunoassay results.
 
KEYWORDS
 
Benzodiazepines, offender population, urine drug testing.
 
INTRODUCTION
 
In several European countries, drug users constitute a
significant proportion of  the prison population. The
results of  several studies indicate that the problem exists
before detention and cannot be stopped by the prison
walls [1,2]. Control of  drugs entering the prison where
this study was performed was carried out by checking the
luggage of  visitors and also by searching the prisoners
before they returned to their cells. However, addicted pris-
oners use great ingenuity to smuggle drugs into prison
and the measures taken are not always effective. In
prison, drugs are circulating in subcultures and those
who refuse to cooperate can fall victim of  fights,
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aggression or threats. This atmosphere forces prisoners to
use drugs and hampers the management of  the institu-
tion. To be in control of  the situation hypnotics and sed-
atives such as benzodiazepines are often prescribed and
their use is widespread among prisoners. Both illegal and
medical drug use can occur in prison [2–5].
Self-reported drug use is often under-reported when
compared with the analysis of  urine or hair [6–8]. Fraser
 
et al
 
. [9] described the results of  the Canadian urine drug
screening programme for 1999 and concluded that urine
drug testing provided an objective measure of  drug use by
offenders in Canadian federal institutions and those liv-
ing in the community on conditional release.
The capability of  immunological screening and gas
chromatographic-mass spectrometric (GC-MS) analysis
of  urine to evaluate the benzodiazepine (mis)use in a
prison population was compared in a longitudinal study.
 
MATERIALS AND METHODS
 
Samples
 
Urine samples were collected in a Belgian house of  deten-
tion for male prisoners between February and August
1998. Every imprisoned person was informed about the
study and was asked to cooperate. An important task of
the medical staff  was to motivate people, although partic-
ipation had to be on a voluntary basis. Participation in
the study did not affect the prisoner treatments and writ-
ten informed consent was obtained in each case. Urine
samples were collected in accordance to the standards of
the ethical review committee of  the Ghent University
Hospital. The prisoners to be tested were collected from
their cells by a guard and brought to the physicians’
room. Surveillance of  a nurse was recommended to pre-
vent dilution or adulteration of  the samples. A total of
530 urine specimens were collected on four test days: on
the day of  arrival (day 0) and after 14 days (day 14),
1 month (day 30) and 3 months (day 90) of  incarcera-
tion. The plastic containers were labelled with the serial
number of  the volunteer and the sampling day, and stored
at 
 
-
 
20
 
∞
 
C until analysis.
 
METHODS
 
All samples were tested for creatinine and screened for
the presence of  benzodiazepines by EMIT
 
®
 
. The kits were
obtained from Syva Co. (Dade Behring Inc., Cupertino,
CA, USA) and were used on a Cobas Mira Instrument
(Roche, Basel, Switzerland). The detection limit (cut-off
value) of  the benzodiazepine assay corresponds to
0.2 mg/l of  oxazepam, as specified in Syva’s instructions.
The assay was calibrated daily with the low (0.2 mg/l
oxazepam) and high (1.0 mg/l oxazepam) calibrators and
the calibration was validated by assaying positive and
negative controls. Unknowns were determined from the
calibration curve by linear interpolation. A sample that
gave a change in absorbance (
 
D
 
A) equal to or higher than
the low calibrator was interpreted as positive, a sample
that gave a change in absorption higher than the high
calibrator was diluted until the value was within the lin-
ear range.
Enzymatic hydrolysis was performed as an initial step
for the subsequent solid-phase extraction and GC-MS
analysis. The method was validated for oxazepam, a com-
mon metabolite of  several benzodiazepines, and for 14
other benzodiazepine compounds [10,11]. As in many
samples bromazepam, diazepam, prazepam and
temazepam were also identified, the recoveries for these
compounds were determined at three different concen-
trations: 5 ng/ml, 100 ng/ml and 1000 ng/ml (
 
n
 
 
 
=
 
 4).
They ranged from 85% to 93% (CV% 
 
<
 
 12%), from 81%
to 96% (CV% 
 
<
 
 11%), from 82% to 93% (CV% 
 
<
 
 14%)
and from 86% to 95% (CV% 
 
<
 
 10%), respectively, indicat-
ing that the optimized GC-MS procedure also allows reli-
able detection of  these benzodiazepines. Interpretation of
the GC-MS results was based on the limit of  detection
(LOD) for the studied benzodiazepines (13–30 ng/ml)
while for all other drug compounds the spectra had to be
in accordance with those from the used MS library for at
least 85%. Samples were interpreted negative for a spe-
cific (illegal) drug, if  the spectral quality was lower.
 
Statistical analysis
 
Results of  the benzodiazepine testing on day 14 was com-
pared with day 0, day 30 with day 14 and day 90 with
day 30.
Immunological screening results in binary data (pres-
ence or absence of  benzodiazepines) and analysis was
based on McNemar’s test [12]. The full GC-MS data can be
summarized as the number of  different benzodiazepines
found and the analysis was based on the change in num-
ber of  benzodiazepines taken using the signed rank test
[13]. The effect of  the false negative rate of  the immunoas-
say compared to GC-MS was assessed by an additional
analysis with dichotomized GC-MS results (GC-MS
binary) using McNemar’s test.
A strategy that is often used for screening consists of
first determining the presence of  benzodiazepines by an
immunoassay, whereupon all positive samples are analy-
sed further by GC-MS (EMIT/GC-MS). In order to compare
this strategy with the more time-consuming strategy of
determining all samples by GC-MS, an additional analysis
of  the EMIT/GC-MS data was performed based on the
signed rank test with, however, all immunoassay negative
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samples scored as 0 for the number of  benzodiazepines
found.
 
RESULTS
 
During the test period a total of  598 people were jailed, of
whom 188 (31.4%) volunteered for the project. Decreas-
ing numbers of  samples were collected on follow-up test
days due to remand or transfer of  the prisoners (Table 1).
Only one prisoner refused to cooperate further after
1 month of  incarceration.
All samples were tested first for creatinine and nine
(1.7%) of  them contained less than 20 mg/dl of  creati-
nine (two specimens were collected on day 0, three on day
14, three on day 30 and one on day 90). From these
dilute samples 5-ml instead of  1-ml aliquots were
extracted prior to GC-MS analysis. No signs of  adultera-
tion (turbidity, foaming, altered pH) [14] were detected.
The EMIT and GC-MS results of  the benzodiazepine
analyses are summarized in Table 1. With EMIT screen-
ing a total of  117 positive benzodiazepine tests (22.1%)
were obtained. All EMIT-positive samples also tested pos-
itive with GC-MS. For GC-MS, a greater rate of  positivity
(in total 174 or 32.8%) was found. Statistical evaluation
of  these data is presented in Fig. 1 (more especially
the statistical difference between day 14 versus day 0).
The most frequently found benzodiazepines with GC-MS
were oxazepam (14.0%) and bromazepam (9.1%).
Lormetazepam (8.3%), temazepam (6.4%), diazepam
(4.5%) and alprazolam (4.5%) were also commonly iden-
tified. Flurazepam (1.5%), flunitrazepam (0.4%) and
prazepam (0.4%) were detected in only a few samples.
The number of  different benzodiazepines identified by
GC-MS (primary and secondary agents) in the corre-
sponding number of  samples is listed in Table 2. From the
174 GC-MS-positive urine specimens, 119 (68.4%) con-
tained only one benzodiazepine, whereas in the others
multiple benzodiazepine (mis)use was demonstrated. In
one sample, up to seven different benzodiazepines could
even be identified.
No significant change in benzodiazepine (mis)use
from day 0 to day 14 could be demonstrated when basing
McNemar’s test on the EMIT results (
 
P
 
 
 
=
 
 0.052) com-
pared to a significant increase for the binary GC-MS
results (
 
P
 
 
 
<
 
 0.0001)(Fig. 1). Based on the analysis of  the
EMIT/GC-MS results or GC-MS full data, the change in
number of  benzodiazepines taken was evaluated using
the signed rank test. Analysis of  the EMIT/GC-MS results
yielded no significant change in benzodiazepine (mis)use
while with the GC-MS full data a significant increase in
the number of  benzodiazepines taken from day 0 to day
14 (
 
P
 
 
 
=
 
 0.0003) was obtained, with 28 subjects taking
one additional benzodiazepine (
 
+
 
1) and 11 subjects tak-
ing more than one additional benzodiazepine (
 
+
 
2 or 
 
+
 
3).
No significant differences were found for any of  the tests
 
Table 1
 
Number of samples tested positive for benzodiazepines with EMIT or GC-MS.
 
Day 0 Day 14 Day 30 Day 90 Total
 
No. of samples 188 170 135 37 530
EMIT
 
+
 
36 (19.1%) 40 (23.5%) 31 (23.0%) 10 (27%) 117 (22.1%)
GC-MS
 
+
 
49 (26.1%) 64 (37.6%) 49 (36.3%) 12 (32.4%) 174 (32.8%)
 
Figure 1
 
Change in benzodiazepine use
from day 0 to day 14 based on EMIT and
GC-MS results. GC-MS binary: GC-MS
data reduced to binary results. With these
binary data it can only be investigated
whether prisoners start (
 
+
 
1) or stop (
 
-
 
1)
using benzodiazepines. EMIT-GCMS: EMIT
screening with GC-MS confirmation of the
positive screening results. Based on these
data and the GC-MS results the difference
in number of benzodiazepines found (–2
to 
 
+
 
3) can additionally be examined (fre-
quency equals the number of samples).
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performed when comparing the (mis)use on day 30 ver-
sus day 14, and day 90 versus day 30.
The EMIT- and GC-MS-positive results were also com-
pared to the doctor’s prescriptions to discriminate
between legal and illegal benzodiazepine use. Samples
collected on the day of  arrival could not be used for this
purpose as these data reflect only the benzodiazepine
(mis)use of  the volunteers before detention, and it was
unknown whether or not the benzodiazepines found at
that time were prescribed. Based on the EMIT results, 22
of  221 samples (10.0%) were found positive, although no
benzodiazepines were prescribed. For GC-MS, the number
of  positive samples was 41 (18.6%). From the 103
samples collected from prisoners who were prescribed
benzodiazepines, 47 (45.6%) contained no benzodiaz-
epines by EMIT, 25 (24.3%) by GC-MS. Remarkably, non-
prescribed benzodiazepines were detected in 50 (48.5%)
of  103 samples from subjects who were prescribed a par-
ticular benzodiazepine. A detailed comparison between
the GC-MS full data and the benzodiazepines prescribed is
summarized in Table 3.
Finally, the frequency of  positive findings for other
legal and illegal drug classes by GC-MS analysis is found
in Table 4. These compounds were not searched for inten-
tionally and prescription data for these agents were not
available. A total of  102 samples (19.2%) were found pos-
itive for illegal drugs, most often amphetamines, cannab-
inoids, cocaine and morphine. The highest legal drug
positive rates were found for analgesics (i.e. naproxen,
ibuprofen, tramadol, naloxone) (7.5%), antidepressants
(i.e. mianserin, trazodone) (4.5%) and neuroleptics (i.e.
clotiapine, pipamperone, prothipendyl) (4.5%).
 
DISCUSSION
 
Urine drug tests are a more objective measure of  drug use
than questionnaires or interviews [9]. In most analytical
studies immunoassay techniques such as EMIT
 
®
 
 are
applied for drug screening, as they are fast and only small
sample volumes are required. In these studies only the
 
Table 2
 
Number of different benzodiazepines identified in the
samples.
 
No. of
benzodiazepines
No. of samples
 
 
 
Day 0 Day 14 Day 30 Day 90 Total
 
1 32 46 33 8 119
2 12 12 7 3 34
3 4 3 4 1 12
4 1 3 4 – 8
5 – – – – –
6 – – – – –
7 – – 1 – 1
Total 49 64 49 12 174
 
Table 3
 
Comparison of the GC-MS full data to the doctor’s prescriptions.
 
Benzodiazepine
Prescribed Not prescribed
 
 
 
No. of patients Present Absent No. of patients Present Absent
 
Oxazepam (Seresta
 
®
 
) 1 1 – 323 51 272
Diazepam (Valium
 
®
 
) 9 3 6 315 12 303
Temazepam (Levanxol
 
®
 
) – – – 324 22 302
Bromazepam (Lexotan
 
®
 
) 38 17 21 286 13 273
Alprazolam (Xanax
 
®
 
) 14 9 5 310 11 299
Lormetazepam (Serenase
 
®
 
) 20 15 5 304 17 287
Flunitrazepam (Rohypnol
 
®
 
) 1 – 1 323 1 322
Flurazepam (Staurodorm
 
®
 
) – – – 324 4 320
Prazepam (Lysanxia
 
®
 
) 1 – 1 323 2 321
 
Table 4
 
Frequency of positive findings for legal and illegal drug classes by GC-MS analysis.
 
Drug classes Day 0 Day 14 Day 30 Day 90 Total
 
No. of samples 188 170 135 37 530
Benzodiazepines 49 (26.1%) 64 (37.6%) 49 (36.3%) 12 (32.4%) 174 (32.8%)
Illegal drugs 45 (23.9%) 27 (15.9%) 26 (19.3%) 4 (10.8%) 102 (19.2%)
Analgesics 9 (4.8%) 16 (9.4%) 12 (8.9%) 3 (8.1%) 40 (7.5%)
Antidepressants 6 (3.2%) 10 (5.9%) 7 (5.2%) 1 (2.7%) 24 (4.5%)
Neuroleptics 10 (5.3%) 5 (2.9%) 8 (5.9%) 1 (2.7%) 24 (4.5%)
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presumptive positive samples are confirmed by specific
chromatographic methods [9,15]. Depending on the
drugs examined and the purpose of  the study, immunoas-
say screening techniques have proved to be very useful as
timely and cost-effective results are obtained. However,
from Table 1 it is clear that false negative results are often
obtained when using immunoassay screening for benzo-
diazepines compared to GC-MS. For example, 36 positive
samples for benzodiazepines (19.1%) were found on day
0 with EMIT, whereas the true rate is 49 positives
(26.1%), as confirmed by GC-MS. The high false negative
rate is the main reason for underestimating the problem
of  benzodiazepine (mis)use in a prison population when
basing conclusions on EMIT results.
An additional drawback of  immunoassay is the
inability to identify specific benzodiazepines. The GC-MS
full data allow not only the compounds with the highest
prevalence of  (mis)use to be identified as oxazepam and
bromazepam, but also allow investigation of  whether
the frequency of  benzodiazepine (mis)use changes over
time, based on the number of  benzodiazepines taken
(Table 2).
The pharmacokinetic profile and metabolism of  ben-
zodiazepines are often complex. Oxazepam is a metabolite
of  several benzodiazepines and also temazepam can be
formed during the metabolism of, e.g. diazepam. Both
compounds can be used as primary agents as well. The
half-lives of  benzodiazepines can be up to several days but
they vary considerably among individuals. Because of  the
heavy reliance on hepatic mechanisms the elimination of
benzodiazepines may be reduced significantly in patients
with inefficient hepatic functioning. Therefore, it should
be noted that the presence of  oxazepam and temazepam
can possibly be attributed to metabolism.
To determine ‘illegal’ benzodiazepine (mis)use the
obtained analytical results need to be compared with the
physicians’ prescriptions (Table 3). Based on an immu-
noassay it is impossible to make a correct assessment
about the problem of  illegally taken benzodiazepines. If
the analysis is based on subjects who are not prescribed
benzodiazepines, it can only be stated that a subject is
using benzodiazepines illegally in the case of  a positive
test result being obtained. In the subpopulation of  prison-
ers that are on benzodiazepine prescription, no discrimi-
nation between prescribed or illegally taken
benzodiazepines can be made. Thus studying these two
subpopulations can only be conducted effectively with
the GC-MS full data. The GC-MS results obtained indicate
that illegal benzodiazepine (mis)use is a major problem in
the subpopulation that already takes prescribed benzodi-
azepines (48.5% 
 
>>
 
 18.6%).
Another advantage of  GC-MS analysis is the possibility
of  detecting other legal and illegal drugs during the same
analysis. The data summarized in Table 4 demonstrate
that 23.9% of  the volunteers were positive for illegal
drugs on the day of  arrival. Although this percentage
decreases during detention, illegal drugs remain present
and must therefore be circulating in this prison.
 
CONCLUSIONS
 
The present longitudinal study provides valuable infor-
mation on the (mis)use of  benzodiazepines in a Belgian
detention house. Performing immunological screening,
even followed by GC-MS confirmation of  the presumptive
positive samples, yields an underestimation of  the prob-
lem. This is due to the high false negative rate of  the
immunological screening. GC-MS analysis of  all samples
is therefore the preferred analytical strategy for the eval-
uation of  benzodiazepine (mis)use. Moreover, additional
data on the identity and the number of  benzodiazepines
are thus obtained. Although it is clear that the work-load
and the costs increase significantly, the results obtained
give a far more correct view on benzodiazepine (mis)use
compared to immunological screening. We suggest that
these results should be kept in mind when setting up the
analytical strategy for similar longitudinal studies on
drug (mis)use or during the interpretation of  results
obtained, e.g. by immunological screening alone. The
authors are convinced that strategies leading to an
underestimation of  the problem are unhelpful in the com-
bat against drug (mis)use.
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